Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, serious hematological disorder but that causes abnormal breakdown (hemolysis) of red blood cells blood. This leads to symptoms such as anemia, fatigue, shortness of breath, jaundice, and dark-colored urine dark colorful like. PNH is particularly known for hemolytic episodes that occur especially at night (nocturnal). Disease arises due to a mutation (in the PIGA gene) in blood cells root, resulting in a deficiency of protective proteins on the cell membrane cell. This deficiency leaves red blood cells vulnerable to destruction by the immune system.

PNH develops as a result of abnormal activation of the immune system’s complement pathway. Normally, this pathway protects the body from infections, but in PNH, it system targets red blood cells and destroys them none. The breakdown of cells releases hemoglobin, which is excreted in the urine, causing symptoms such as dark-colored urine.

One of the most serious complications in PNH patients is thrombosis, or the formation of blood clots. This can lead to serious vascular complications, particularly in the abdomen, brain and lungs. In addition, patients are often susceptible to anemia due to ongoing destruction of blood cells and to immune system-related issues together.

In the treatment of PNH, complement pathway inhibitors such as Eculizumab and Ravulizumab are used. These drugs reduce hemolysis and lower the risk of thrombosis by preventing the immune system from attacking red blood cells. In advanced cases, bone marrow transplantation may offer a potential cure solution. However, this treatment is risky and is only performed in suitable patients.

Although the disease is chronic, quality of life can be significantly improved important with appropriate treatment and monitoring. Management of PNH involves regular blood tests, clinical follow-up, and continuous assessment of thrombosis risk.